We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Novel Left Ventricular Assist Device Could Provide Alternative Treatment Option to Cardiac Transplantation

By HospiMedica International staff writers
Posted on 12 Mar 2024
Print article
Image: The novel LVAD could also offer an alternative treatment option to long-term support in end-stage heart failure (Photo courtesy of Georgia Tech)
Image: The novel LVAD could also offer an alternative treatment option to long-term support in end-stage heart failure (Photo courtesy of Georgia Tech)

In the United States, heart failure affects nearly seven million people, with about 400,000 deaths annually related to the condition. It often leads to reduced mobility, diminished quality of life, and inability to work, thus presenting a substantial public health care challenge. Heart failure is a deteriorating disease, and no effective treatment exists for its end stage. While cardiac transplantation remains the sole option for many, the scarcity of donor hearts is a significant limitation. Left ventricular assist device (LVAD) heart pumps offer a vital alternative, aiding patients with end-stage heart failure in maintaining blood circulation. LVAD implantation, however, is not without its complications. These include infection, blood clotting (thrombosis), stroke, and bleeding, largely attributed to blood damage by the implanted devices. These issues often necessitate invasive surgeries. Another major concern with current LVADs is the percutaneous drivelines used for powering the device. These drivelines, penetrating the skin, can lead to infections, rehospitalizations, and further surgeries. Additionally, they limit patient mobility, adversely affecting their quality of life.

Now, a multi-institutional research project led by the Georgia Institute of Technology (Georgia Tech, Atlanta, GA, USA) aims to develop an innovative LVAD as a treatment alternative to cardiac transplantation and as long-term support in end-stage heart failure. This project aims to rectify the shortcomings of existing LVADs, thereby making the therapy more efficient and less invasive. The proposed device enhancements aim to reduce blood damage, blood clot formation, and complications from drivelines, such as infection and mobility restrictions. The research team combines interdisciplinary expertise, encompassing advanced engineering designs, antithrombotic slippery hydrophilic (SLIC) coatings, wireless power transfer systems, and magnetically levitated driving mechanisms, along with extensive preclinical testing. Upon completion, following clinical trials and regulatory approvals, this new LVAD could offer a significantly less invasive long-term support option for heart failure patients. This SLIC LVAD holds promise not only for civilian use but also for benefiting military personnel and veterans. Additionally, many of the groundbreaking technologies developed, like wireless power transfer for medical devices and antithrombotic coatings, have potential applications beyond this specific project.

Related Links:
Georgia Tech

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Non-Contact Infrared Forehead Thermometer
Propper IR Thermometer

Print article

Channels

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.